Enanta has outlined a strategy to gain leadership in the treatment of respiratory syncytial virus (RSV). Enanty's portfolio includes RSV replication inhibitors with the potential to become the first and best treatment for this disease. The company is actively advancing its development program in the field of RSV and immunology. There are plans to meet with the FDA to agree on a phase 3 study design in adult patients. This meeting is scheduled for the second quarter of 2026. Enanta expects key milestones in the near term of its pipeline.